Literature DB >> 7679751

Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.

A Benjouad1, J C Gluckman, L Montagnier, E Bahraoui.   

Abstract

In a previous report we have shown that, in contrast to antibodies produced against native or fully deglycosylated human immunodeficiency virus type 1 (HIV-1) gp160 in rabbits, antibodies raised against desialylated HIV-1 gp160 also recognize gp140 from HIV-2 at high titers. Here, we characterize the fine specificity of these cross-reactive antibodies. Inhibition assays with a panel of synthetic peptides as competitors showed that cross-reactivity to gp140 was due to antibodies that were specific for the region encompassing HIV-1 gp41 immunodominant epitope, mimicked by peptide P39 (residues 583 to 609), the latter being able to totally inhibit the formation of complexes between radiolabeled HIV-2 gp140 and antibodies elicited by desialylated HIV-1 gp160. In addition, anti-desialylated gp160 antibodies retained on a P39 affinity column still bound HIV-2 gp140. Fine mapping has enabled us to localize the cross-reactive epitope within the N-terminal extremity of the gp41 immunodominant region. Interestingly, this cross-reactive antibody population did not recognize glycosylated or totally deglycosylated simian immunodeficiency virus gp140 despite an amino acid homology with HIV-1 within this region that is comparable to that of HIV-2. This cross-reactivity between HIV-1 and HIV-2 did not correlate with cross-neutralization. These results illustrate the influence of carbohydrate moieties on the specificity of the antibodies produced and clearly indicate that such procedures may be an efficient way to raise specific immune responses that are not type specific. Moreover, this cross-reactivity might explain the double-positive reactivity observed, in some human sera, against both HIV-1 and HIV-2 envelope antigens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679751      PMCID: PMC237545     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

Authors:  B Böttiger; A Karlsson; P A Andreasson; A Nauclér; C M Costa; E Norrby; G Biberfeld
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

2.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

3.  Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.

Authors:  J J Wang; S Steel; R Wisniewolski; C Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

5.  Carbohydrate side chains of Rauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response.

Authors:  J H Elder; J S McGee; S Alexander
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

6.  A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody.

Authors:  J J Skehel; D J Stevens; R S Daniels; A R Douglas; M Knossow; I A Wilson; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

7.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens.

Authors:  S Alexander; J H Elder
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

9.  Study of the interaction of HIV-1 and HIV-2 envelope glycoproteins with the CD4 receptor and role of N-glycans.

Authors:  E Bahraoui; A Benjouad; D Guetard; H Kolbe; J C Gluckman; L Montagnier
Journal:  AIDS Res Hum Retroviruses       Date:  1992-05       Impact factor: 2.205

10.  Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells.

Authors:  M L Smiley; H M Friedman
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  5 in total

1.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

2.  Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Authors:  A Fournillier; C Wychowski; D Boucreux; T F Baumert; J C Meunier; D Jacobs; S Muguet; E Depla; G Inchauspé
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.

Authors:  R E Means; R C Desrosiers
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revert.

Authors:  W K Wang; M Essex; T H Lee
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Flow cytometric immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 1 using insoluble precursor forms of recombinant polyproteins as carriers and antigens.

Authors:  Y W Hu; P Birch; E Balaskas; A Zeibdawi; V Scalia; S A Thériault-Valin; P Gill; M T Aye
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.